Haleon Buys Back Shares for £11.9M
Ticker: HLNCF · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-buyback, treasury-shares
TL;DR
Haleon just bought back 1.5M shares for £11.9M. Looks like they think their stock is cheap.
AI Summary
Haleon plc announced on August 29, 2025, that it repurchased 1,500,000 of its ordinary shares at prices ranging from £7.90 to £8.00 per share. The total cost of these repurchases was approximately £11.9 million. These shares were bought on the London Stock Exchange and will be held as treasury shares.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share, which may be viewed positively by investors.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any significant new risks.
Key Numbers
- 1.5M — Shares Repurchased (Haleon plc bought back 1.5 million ordinary shares.)
- £11.9M — Total Cost (The total expenditure for the share repurchase program was approximately £11.9 million.)
Key Players & Entities
- Haleon plc (company) — Registrant
- 1,500,000 (dollar_amount) — Number of shares repurchased
- £7.90 (dollar_amount) — Minimum repurchase price
- £8.00 (dollar_amount) — Maximum repurchase price
- £11.9 million (dollar_amount) — Total cost of repurchases
- August 29, 2025 (date) — Date of transaction
FAQ
What was the total number of ordinary shares repurchased by Haleon plc?
Haleon plc repurchased a total of 1,500,000 ordinary shares.
On what date did Haleon plc conduct these share transactions?
The transactions occurred on August 29, 2025.
What was the approximate total cost of the share repurchases?
The approximate total cost of the repurchases was £11.9 million.
Where were the shares repurchased?
The shares were repurchased on the London Stock Exchange.
What will happen to the repurchased shares?
The repurchased shares will be held as treasury shares.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-29 06:07:04
Filing Documents
- a1293x.htm (6-K) — 34KB
- a1293x000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010162.txt ( ) — 40KB
From the Filing
IN OWN SHARES a1293x   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of August 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description           99.1 29 August 2025 - Transaction in Own Shares       99.1     Haleon plc:   Transaction in own shares   29 August 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 2,191,437 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 28 August 2025 28 August 2025 28 August 2025 Number of Shares purchased: 2,191,437 - - Highest price paid per Share (p): 364.0000 - - Lowest price paid per Share (p): 359.9000 - - Volume weighted average price paid per Share (p): 361.6800 - -   Following the settlement of the above, the Company's registered share capital   is 8,961,283,874 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,957,403,669 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/1291X_1-2025-8-28.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .          SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: August 29, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary